ABL Bio's 'ABL111' Wins Best Poster Award at ESMO
ABL Bio (ABL Bio) announced on the 24th that the poster containing clinical phase 1 data of the bispecific antibody pipeline 'ABL111 (TJ-CD4B, generic name Gibastomic)' introduced at the '2023 European Society for Medical Oncology (ESMO 2023)' won the 'Best Poster Award' in the clinical stage immuno-oncology poster session.
ABL111 is a bispecific antibody pipeline co-developed by ABL Bio and I-Mab, a Nasdaq-listed Chinese company. The poster presentation at this ESMO was also handled by I-Mab. The poster included analyses of the dose escalation and dose expansion parts of the ongoing phase 1 clinical trial of ABL111 in the United States and China. It was explained that this poster received much attention and favorable reviews from attendees at ESMO and was selected as the best poster in the session.
Lee Sang-hoon, CEO of ABL Bio, said, “This is the first time clinical data of ABL111, a pipeline applying the 4-1BB bispecific antibody platform Grabody-T, has been disclosed. I am very pleased to hear that it received such a good response as to win the Best Poster Award.”
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
On the morning of the 25th, ABL Bio plans to hold a corporate presentation for investors and others to enhance understanding of its research and development (R&D) status and future plans through its YouTube channel. Detailed interim results of the phase 1 clinical trial included in the ABL111 poster will also be shared there.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
